Breast cancer patterns by age groups in Brazil: insights from population-based registries data.

BMC Cancer

Division of Clinical Research and Technological Development, Brazilian National Cancer Institute, 37 Andre Cavalcanti Street, 5th floor, Annex Building, 20231050, Rio de Janeiro, Brazil.

Published: January 2025

Background: Breast cancer (BC) has exhibited varied epidemiological trends based on distinct age categories. This research aimed to explore the incidence and mortality rates of BC within pre-defined age groups in the Brazilian population.

Methods: BC incidence trends were assessed from 2010 to 2015 using Brazilian Population-Based Cancer Registries, employing age-standardized ratios and annual average percentage change (AAPC). Hospital-Based Cancer Registries provided clinical and sociodemographic data from 2000 to 2019. Mortality data were obtained from the National Mortality Information System from 2000 to 2020. Three groups were compared: < 40, 40-69, and ≥ 70 years.

Results: From 2010 to 2015, 205,966 new BC cases were recorded, with incidence rates of 7.1/100,000 for < 40, 156.5/100,000 for 40-69, and 247.5/100,000 for ≥ 70 years. The < 40 years group exhibited a significant increase in incidence rate (AAPC + 1.6; 95% CI: 1.0 to 2.2; p < 0.001). This age group also showed a higher proportion of black patients (53%, p < 0.001), alcohol consumption (20.5%, p < 0.001), proportion of patients treated at stages ≥ IIB (64.0%, p < 0.001), and a higher likelihood of receiving multiple treatment modalities (60.7%, p < 0.001). The ≥ 70 years group experienced a longer delay exceeding 60 days from diagnosis to treatment onset (54%, p < 0.001), while exhibiting a higher proportion of endocrine therapy utilization (45.3%, p < 0.01). Mortality rates increased across all subgroups, with the < 40 years group showing the most pronounced increase (AAPC + 1.8%; 95% CI: 1.6 to 2.1; p < 0.001).

Conclusion: These results highlight marked disparities in BC incidence, mortality rates, clinicopathological and sociodemographic characteristics between women under 40, and those in the 40-69 and ≥ 70 age groups in Brazil.

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-024-13381-5DOI Listing

Publication Analysis

Top Keywords

breast cancer
8
age groups
8
cancer registries
8
cancer patterns
4
patterns age
4
groups brazil
4
brazil insights
4
insights population-based
4
population-based registries
4
registries data
4

Similar Publications

Novel MRI-based Hyper-Fused Radiomics for Predicting Pathologic Complete Response to Neoadjuvant Therapy in Breast Cancer.

Acad Radiol

January 2025

Imaging Center, Harbin Medical University Cancer Hospital, Haping Road No.150, Nangang District, Harbin 150081, China (Q-X.C., L-Q.Z., X-Y.W., H-X.Z., J-J.L., M-C.X., H-Y.S., Z-X.K.). Electronic address:

Rationale And Objectives: To propose a novel MRI-based hyper-fused radiomic approach to predict pathologic complete response (pCR) to neoadjuvant therapy (NAT) in breast cancer (BC).

Materials And Methods: Pretreatment dynamic contrast-enhanced (DCE) MRI and ultra-multi-b-value (UMB) diffusion-weighted imaging (DWI) data were acquired in BC patients who received NAT followed by surgery at two centers. Hyper-fused radiomic features (RFs) and conventional RFs were extracted from DCE-MRI or UMB-DWI.

View Article and Find Full Text PDF

Purpose: Male breast cancer is an understudied disease with unique clinicopathological features. This study aims to evaluate the predictive value of the Clinical Treatment Score post-5 years (CTS5) in estimating late recurrence risk in estrogen receptor-positive (ER+) male breast cancer patients.

Methods: This retrospective study includes 65,711 ER+ early male (n = 611) and female (n = 65,100) breast cancer patients from the Surveillance, Epidemiology, and End Results (SEER) database diagnosed between 2010 and 2018.

View Article and Find Full Text PDF

Background: Risk reducing mastectomy (RRM) is an option for women with pathogenic germline variants in BRCA1 or BRCA2 (BRCA1/2). This study investigates and compares RRM-uptake among Norwegian BRCA1/2 carriers from 2008 to 2021, temporal trends, and incidence of breast cancer (BC) after surgery.

Methods: BRCA1/2 carriers without prior breast or ovarian cancer, tested at Oslo University Hospital between January 1st 2008 and December 31st 2021 were included in the study.

View Article and Find Full Text PDF

Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer.

ESMO Open

January 2025

Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain; Reveal Genomics, Barcelona, Spain. Electronic address:

Background: The infiltration of tumor-infiltrating B cells and plasma cells in early-stage breast cancer has been associated with a reduced risk of distant metastasis. However, the influence of B-cell tumor infiltration on overall patient survival remains unclear.

Materials And Methods: This study explored the relationship between an antitumor immune response, measured by a 14-gene B-cell/immunoglobulin (IGG) signature, and mortality risk in 9638 breast cancer patients across three datasets.

View Article and Find Full Text PDF

For the first time, our study provides a comprehensive examination of the anti-cancer effects of structural isomers of carene in breast cancer cells, specifically focusing on cell cycle inhibition and the induction of apoptosis. We utilized the hydro-distillation method to extract Piper nigrum seed essential oil (PNS-EO) and identified its bioactive components through gas chromatography-mass spectrometry (GC-MS) analysis. A total of 46 bioactive compounds were isolated via hydro-distillation, identified through GC-MS analysis, and validated by co-injection using GC analysis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!